Protein glycation products associate with progression of kidney disease and incident cardiovascular events in individuals with type 1 diabetes
Authors' conclusion
Overall, these findings suggest that protein glycation products are an important risk factor for target organ damage in type 1 diabetes. The data provide further support to investigate a potential causal role of serum protein glycation in the progression of diabetes complications.
Study context
- Population
- Individuals with T1D, FinnDiane study
- Participants
- 575 individuals
- Exposure
- Serum protein glycation products (fructosamine, AGEs, MG-H1) and kidney disease progression and incident major adverse cardiovascular events (MACE)
- Outcome
- Kidney disease progression (steep eGFR decline >3 mL/min/1.73 m²/year or albuminuria progression) and incident MACE
Main finding
As reported in the abstract
- Fructosamine and steep eGFR decline, fully adjusted (age, sex, baseline eGFR): OR [95% CI 1.16-4.01], p = 0.016
- 2.15
- AGEs and steep eGFR decline: OR per 1 unit of SD [95% CI 1.07-2.32], p = 0.02
- 1.58
- AGEs and progression to end-stage kidney disease (ESKD): HR per 1 unit of SD [95% CI 1.43-3.05], p < 0.001
- 2.09
- AGEs and pooled progression (to any stage of albuminuria): HR per 1 unit of SD [95% CI 2.04-3.62], p < 0.001
- 2.72
- AGEs and incident MACE: HR per 1 unit of SD [95% CI 1.23-2.00], p < 0.001
- 1.57
- MG-H1 and incident MACE: HR [95% CI 0.98-25.55], p = 0.054
- 4.99
- MG-H1 and pooled progression: HR [95% CI 1.11-15.89], p = 0.035
- 4.19
Observational data: associations, not effects.
Original publication
Protein glycation products associate with progression of kidney disease and incident cardiovascular events in individuals with type 1 diabetes. Cardiovasc Diabetol. Published 4 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →